Advertisement
Screener

VolitionRx Limited (VNRX) Net Income (Loss) Allocated to Limited Partners

2.6 / 5 stars · 32/62 Roast Me

VolitionRx Limited Net Income (Loss) Allocated to Limited Partners

VolitionRx Limited (VNRX) reported Net Income (Loss) Allocated to Limited Partners of -$7.33 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:NetIncomeLossAllocatedToLimitedPartners · last filed 2026-08-13

  • VolitionRx Limited net income (loss) allocated to limited partners for the quarter ending 2026-06-30 was -$7.33M.
  • VolitionRx Limited net income (loss) allocated to limited partners for the quarter ending 2025-06-30 was -$6.28M.
Period endNet Income (Loss) Allocated to Limited Partners 3 monthNet Income (Loss) Allocated to Limited Partners 6 month
2026-06-30-$7.33M
10-Q · filed 2026-08-13
-$13.99M
10-Q · filed 2026-08-13
2025-06-30-$6.28M
10-Q · filed 2026-08-13
-$11.71M
10-Q · filed 2026-08-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cardio Diagnostics Holdings, Inc. (CDIO)United States$0.006B
Q/C TECHNOLOGIES, INC. (QCLS)United States$0.008B-1.93
BIOMERICA INC (BMRA)United States$0.011B
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92